Veracyte, Inc. (NASDAQ:VCYT) Shares Sold by Strs Ohio

Strs Ohio cut its stake in Veracyte, Inc. (NASDAQ:VCYT) by 4.0% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 33,300 shares of the biotechnology company’s stock after selling 1,400 shares during the period. Strs Ohio’s holdings in Veracyte were worth $916,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. grew its position in Veracyte by 96.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,862 shares of the biotechnology company’s stock valued at $42,000 after acquiring an additional 913 shares during the period. CWM LLC increased its position in Veracyte by 533.0% during the 3rd quarter. CWM LLC now owns 2,146 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 1,807 shares in the last quarter. Asset Management One Co. Ltd. purchased a new position in Veracyte in the third quarter valued at approximately $84,000. Assetmark Inc. lifted its position in Veracyte by 16.9% during the third quarter. Assetmark Inc. now owns 8,573 shares of the biotechnology company’s stock valued at $191,000 after buying an additional 1,239 shares in the last quarter. Finally, Inspire Investing LLC purchased a new stake in Veracyte during the third quarter worth approximately $307,000.

Veracyte Price Performance

Shares of VCYT opened at $19.90 on Thursday. Veracyte, Inc. has a one year low of $18.61 and a one year high of $30.52. The stock has a 50-day moving average price of $21.82 and a 200 day moving average price of $23.91.

Veracyte (NASDAQ:VCYT) last released its earnings results on Thursday, February 22nd. The biotechnology company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.03. Veracyte had a negative return on equity of 2.02% and a negative net margin of 20.61%. The company had revenue of $98.20 million during the quarter, compared to analysts’ expectations of $95.49 million. On average, equities research analysts anticipate that Veracyte, Inc. will post -0.29 earnings per share for the current year.

Insider Activity at Veracyte

In other Veracyte news, Director Karin Eastham sold 10,000 shares of the firm’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $21.65, for a total transaction of $216,500.00. Following the completion of the transaction, the director now directly owns 33,125 shares of the company’s stock, valued at approximately $717,156.25. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 2.60% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

VCYT has been the topic of several recent research reports. Needham & Company LLC lifted their target price on shares of Veracyte from $30.00 to $33.00 and gave the company a “buy” rating in a report on Friday, February 23rd. William Blair reiterated an “outperform” rating on shares of Veracyte in a report on Friday, February 23rd. Morgan Stanley decreased their price target on Veracyte from $22.00 to $21.00 and set an “underweight” rating for the company in a report on Monday, February 26th. Finally, The Goldman Sachs Group dropped their price objective on shares of Veracyte from $32.00 to $28.00 and set a “buy” rating on the stock in a research note on Monday, April 15th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, Veracyte presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.00.

About Veracyte

Veracyte, Inc operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis.